CClinicalTrials.gg
RecruitingNCT06833619Updated Feb 19, 2025

Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique

An interventional study of Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique in Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Endoscopic ultrasound-guided liver biopsy (EUS-LB) can overcome many shortcomings of percutaneous liver biopsy and TJLB. Targeted and non-targeted liver biopsies can be done through this biopsy. It can be done in patients with international normalized ratio (INR) up to 2. It has less tissue fragmentation compared with TJLB.

Needle entering the liver can be viewed in real-time (intrahepatic vessels and bile duct can be spared from injury) (Sharma et al., 2023). Both lobes of the liver can be accessed. It provides minimal patient discomfort. EUS-LB can access liver lesions that may not be safely accessible by routine US or computed tomography (tenBerge et al., 2002). It provides better results in obese individuals compared with percutaneous liver biopsy. It is safe in pregnant females requiring liver biopsy (Khare et al., 2024). Despite these advantages, EUS-LB is largely limited to tertiary care centers and its use is not yet widespread. This may be because, since its inception, numerous variations in needle shape, needle size, and, most notably, sampling techniques have been adopted.

However, no consensus protocol for acquisition has been recognized, leading to poor procedural standardization and wide ranges of reported outcomes in sample quality and diagnostic yield. As such, there is a substantial need for a uniform technique that will safely maximize diagnostic performance with minimal needle passes (Khare et al., 2024).

02

Conditions studied

  • Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • The participants of the study were adults in need of liver biopsy for the evaluation of Altered liver function test

Exclusion criteria

Exclusion Criteria:

  • Using anti-platelets or anticoagulants within the last 5days
  • Inability to provide informed consent
  • Moderate-to-gross ascites
  • Child C cirrhosis
  • INR more than 2.01
  • Platelet count less than 50,000/µL3
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique

    Device: Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique

Interventions

  • DeviceEfficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique

    Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique

06

What researchers measure

Primary outcomes

  1. Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique

    Measurement the efficacy of liver biopsy specimens by European Association for the Study of Liver Disease (EASL) criteria . - Total Specimen Length (TSL) of more than or equal to 15 mile-meters.

    Time frame: -Study period: Duration of the study will be 12 months after acceptance of The Ethical Committee Of The Medical Research. All patients will sign an informed written consent before starting the data collection with respect to patient's confidentiality.

07

Study locations

1 of 1 sites recruiting
  • Sohag University
    Sohag, Egypt
    • Sara Elbadry Elrabie, master · Contact · 01147045010
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06833619
Lead sponsor
Sohag University
Responsible party
Sara Elbadry Elrabie (Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique, Sohag University) — Principal investigator
First posted
Feb 19, 2025
Start date
Dec 1, 2024
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Sara Elbadry Elrabie, master
Contact
elbadrysara615@gmail.com
01023941334
Sara Elbadry Eirabie, master
study director · Sohag

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion